According to results from the phase 1b DeLLphi-303 trial, maintenance therapy with tarlatamab plus either atezolizumab or durvalumab demonstrated clinical promise among patients with extensive-stage small cell lung cancer.
According to results from the phase 1b DeLLphi-303 trial, maintenance therapy with tarlatamab plus either atezolizumab or durvalumab demonstrated clinical promise among patients with extensive-stage small cell lung cancer.
Dr Fawzi Abu Rous discussed the treatment of a 54-year-old patient who was diagnosed with an atypical case of small cell lung cancer. Which of the following features made this case atypical?
Dr Fawzi Abu Rous discussed the treatment of a 54-year-old patient who was diagnosed with an atypical case of small cell lung cancer. Which of the following features made this case atypical?
According to exploratory subgroup analysis results from the phase 3 CASPIAN trial, durvalumab plus etoposide and carboplatin or cisplatin demonstrated efficacy and safety regardless of age or sex among treatment-naive patients with...
According to exploratory subgroup analysis results from the phase 3 CASPIAN trial, durvalumab plus etoposide and carboplatin or cisplatin demonstrated efficacy and safety regardless of age or sex among treatment-naive patients with...
Fawzi Abu Rous, MD, discusses the treatment of a patient with BRAF V600E-mutated small cell lung cancer who experienced a durable response with targeted therapy.
Fawzi Abu Rous, MD, discusses the treatment of a patient with BRAF V600E-mutated small cell lung cancer who experienced a durable response with targeted therapy.
According to a phase 2 trial, brain-directed stereotactic radiation demonstrated lower rates of neurologic death compared to whole-brain radiation among patients with small cell lung cancer who have 1 to 10 brain metastases.
According to a phase 2 trial, brain-directed stereotactic radiation demonstrated lower rates of neurologic death compared to whole-brain radiation among patients with small cell lung cancer who have 1 to 10 brain metastases.
In the phase 2 REBORN trial, which drug regimen was administered alongside durvalumab, and what does this suggest about the study’s approach to enhancing standard care? Test your knowledge with our quiz!
In the phase 2 REBORN trial, which drug regimen was administered alongside durvalumab, and what does this suggest about the study’s approach to enhancing standard care? Test your knowledge with our quiz!
Final immunophenotypic and biomarker analysis results from the phase 2 PAVE study found that intercalated avelumab plus chemotherapy demonstrated promising efficacy and safety among patients with extensive-stage small cell lung cancer.
Final immunophenotypic and biomarker analysis results from the phase 2 PAVE study found that intercalated avelumab plus chemotherapy demonstrated promising efficacy and safety among patients with extensive-stage small cell lung cancer.
According to results from the phase 3b MAURIS study, first-line atezolizumab plus carboplatin and etoposide demonstrated efficacy and safety in a broad population of patients with extensive-stage small cell lung cancer.
According to results from the phase 3b MAURIS study, first-line atezolizumab plus carboplatin and etoposide demonstrated efficacy and safety in a broad population of patients with extensive-stage small cell lung cancer.
Results from a real-world study demonstrated that compassionate use of lurbinectedin showed efficacy and safety among previously treated patients with extensive-stage small cell lung cancer.
Results from a real-world study demonstrated that compassionate use of lurbinectedin showed efficacy and safety among previously treated patients with extensive-stage small cell lung cancer.
According to results from a retrospective analysis, consolidative thoracic radiotherapy following first-line treatment with chemoimmunotherapy improved intrathoracic control among patients with extensive-stage small cell lung cancer.
According to results from a retrospective analysis, consolidative thoracic radiotherapy following first-line treatment with chemoimmunotherapy improved intrathoracic control among patients with extensive-stage small cell lung cancer.
According to results from the phase 2 REBORN trial, first-line durvalumab plus irinotecan and cisplatin demonstrated potential among patients with extensive-stage small cell lung cancer.
According to results from the phase 2 REBORN trial, first-line durvalumab plus irinotecan and cisplatin demonstrated potential among patients with extensive-stage small cell lung cancer.
According to results from the phase 1b DeLLphi-303 trial, maintenance therapy with tarlatamab plus either atezolizumab or durvalumab demonstrated clinical promise among patients with extensive-stage small cell lung cancer.
According to results from the phase 1b DeLLphi-303 trial, maintenance therapy with tarlatamab plus either atezolizumab or durvalumab demonstrated clinical promise among patients with extensive-stage small cell lung cancer.
According to exploratory subgroup analysis results from the phase 3 CASPIAN trial, durvalumab plus etoposide and carboplatin or cisplatin demonstrated efficacy and safety regardless of age or sex among treatment-naive patients with...
According to exploratory subgroup analysis results from the phase 3 CASPIAN trial, durvalumab plus etoposide and carboplatin or cisplatin demonstrated efficacy and safety regardless of age or sex among treatment-naive patients with...
According to a phase 2 trial, brain-directed stereotactic radiation demonstrated lower rates of neurologic death compared to whole-brain radiation among patients with small cell lung cancer who have 1 to 10 brain metastases.
According to a phase 2 trial, brain-directed stereotactic radiation demonstrated lower rates of neurologic death compared to whole-brain radiation among patients with small cell lung cancer who have 1 to 10 brain metastases.
Final immunophenotypic and biomarker analysis results from the phase 2 PAVE study found that intercalated avelumab plus chemotherapy demonstrated promising efficacy and safety among patients with extensive-stage small cell lung cancer.
Final immunophenotypic and biomarker analysis results from the phase 2 PAVE study found that intercalated avelumab plus chemotherapy demonstrated promising efficacy and safety among patients with extensive-stage small cell lung cancer.
According to results from the phase 3b MAURIS study, first-line atezolizumab plus carboplatin and etoposide demonstrated efficacy and safety in a broad population of patients with extensive-stage small cell lung cancer.
According to results from the phase 3b MAURIS study, first-line atezolizumab plus carboplatin and etoposide demonstrated efficacy and safety in a broad population of patients with extensive-stage small cell lung cancer.
Results from a real-world study demonstrated that compassionate use of lurbinectedin showed efficacy and safety among previously treated patients with extensive-stage small cell lung cancer.
Results from a real-world study demonstrated that compassionate use of lurbinectedin showed efficacy and safety among previously treated patients with extensive-stage small cell lung cancer.
According to results from a retrospective analysis, consolidative thoracic radiotherapy following first-line treatment with chemoimmunotherapy improved intrathoracic control among patients with extensive-stage small cell lung cancer.
According to results from a retrospective analysis, consolidative thoracic radiotherapy following first-line treatment with chemoimmunotherapy improved intrathoracic control among patients with extensive-stage small cell lung cancer.
According to results from the phase 2 REBORN trial, first-line durvalumab plus irinotecan and cisplatin demonstrated potential among patients with extensive-stage small cell lung cancer.
According to results from the phase 2 REBORN trial, first-line durvalumab plus irinotecan and cisplatin demonstrated potential among patients with extensive-stage small cell lung cancer.
Results from the phase 3 IMforte trial demonstrated that lurbinectedin plus atezolizumab improved survival among patients with extensive-stage small cell lung cancer in the first-line maintenance setting.
Results from the phase 3 IMforte trial demonstrated that lurbinectedin plus atezolizumab improved survival among patients with extensive-stage small cell lung cancer in the first-line maintenance setting.
Dr Fawzi Abu Rous discussed the treatment of a 54-year-old patient who was diagnosed with an atypical case of small cell lung cancer. Which of the following features made this case atypical?
Dr Fawzi Abu Rous discussed the treatment of a 54-year-old patient who was diagnosed with an atypical case of small cell lung cancer. Which of the following features made this case atypical?
In the phase 2 REBORN trial, which drug regimen was administered alongside durvalumab, and what does this suggest about the study’s approach to enhancing standard care? Test your knowledge with our quiz!
In the phase 2 REBORN trial, which drug regimen was administered alongside durvalumab, and what does this suggest about the study’s approach to enhancing standard care? Test your knowledge with our quiz!
Did atezolizumab plus etoposide and carboplatin delay time to central nervous system progression among patients with extensive-stage small cell lung cancer?
Did atezolizumab plus etoposide and carboplatin delay time to central nervous system progression among patients with extensive-stage small cell lung cancer?
According to results from the phase 2 SWOG S1929 study, what was the result of adding talazoparib to maintenance atezolizumab among patients with extensive-stage small cell lung cancer?
According to results from the phase 2 SWOG S1929 study, what was the result of adding talazoparib to maintenance atezolizumab among patients with extensive-stage small cell lung cancer?
Did lurbinectedin demonstrate equivalent to or better efficacy than platinum rechallenge among patients with platinum-sensitive small cell lung cancer who experience relapse after treatment with platinum-based therapy?
Did lurbinectedin demonstrate equivalent to or better efficacy than platinum rechallenge among patients with platinum-sensitive small cell lung cancer who experience relapse after treatment with platinum-based therapy?
Did the administration of trilaciclib prior to chemotherapy reduce the incidence of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer?
Did the administration of trilaciclib prior to chemotherapy reduce the incidence of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer?
According to a retrospective study, how did the median PFS of patients with extensive stage SCLC receiving immune checkpoint inhibition and chemotherapy who had inflamed tumors compare to those patients with noninflamed tumors?
According to a retrospective study, how did the median PFS of patients with extensive stage SCLC receiving immune checkpoint inhibition and chemotherapy who had inflamed tumors compare to those patients with noninflamed tumors?
Among patients with limited-stage SCLC, did patients in the PD-L1 positivity group of a phase 2 study published in the European Journal of Cancer experience longer PFS and OS vs patients who were PD-L1 negative when treated with durvalumab...
Among patients with limited-stage SCLC, did patients in the PD-L1 positivity group of a phase 2 study published in the European Journal of Cancer experience longer PFS and OS vs patients who were PD-L1 negative when treated with durvalumab...
According to results from the phase 1b DeLLphi-303 trial, maintenance therapy with tarlatamab plus either atezolizumab or durvalumab demonstrated clinical promise among patients with extensive-stage small cell lung cancer.
According to results from the phase 1b DeLLphi-303 trial, maintenance therapy with tarlatamab plus either atezolizumab or durvalumab demonstrated clinical promise among patients with extensive-stage small cell lung cancer.
According to exploratory subgroup analysis results from the phase 3 CASPIAN trial, durvalumab plus etoposide and carboplatin or cisplatin demonstrated efficacy and safety regardless of age or sex among treatment-naive patients with...
According to exploratory subgroup analysis results from the phase 3 CASPIAN trial, durvalumab plus etoposide and carboplatin or cisplatin demonstrated efficacy and safety regardless of age or sex among treatment-naive patients with...
According to a phase 2 trial, brain-directed stereotactic radiation demonstrated lower rates of neurologic death compared to whole-brain radiation among patients with small cell lung cancer who have 1 to 10 brain metastases.
According to a phase 2 trial, brain-directed stereotactic radiation demonstrated lower rates of neurologic death compared to whole-brain radiation among patients with small cell lung cancer who have 1 to 10 brain metastases.
Final immunophenotypic and biomarker analysis results from the phase 2 PAVE study found that intercalated avelumab plus chemotherapy demonstrated promising efficacy and safety among patients with extensive-stage small cell lung cancer.
Final immunophenotypic and biomarker analysis results from the phase 2 PAVE study found that intercalated avelumab plus chemotherapy demonstrated promising efficacy and safety among patients with extensive-stage small cell lung cancer.
According to results from the phase 3b MAURIS study, first-line atezolizumab plus carboplatin and etoposide demonstrated efficacy and safety in a broad population of patients with extensive-stage small cell lung cancer.
According to results from the phase 3b MAURIS study, first-line atezolizumab plus carboplatin and etoposide demonstrated efficacy and safety in a broad population of patients with extensive-stage small cell lung cancer.
Results from a real-world study demonstrated that compassionate use of lurbinectedin showed efficacy and safety among previously treated patients with extensive-stage small cell lung cancer.
Results from a real-world study demonstrated that compassionate use of lurbinectedin showed efficacy and safety among previously treated patients with extensive-stage small cell lung cancer.
According to results from a retrospective analysis, consolidative thoracic radiotherapy following first-line treatment with chemoimmunotherapy improved intrathoracic control among patients with extensive-stage small cell lung cancer.
According to results from a retrospective analysis, consolidative thoracic radiotherapy following first-line treatment with chemoimmunotherapy improved intrathoracic control among patients with extensive-stage small cell lung cancer.
According to results from the phase 2 REBORN trial, first-line durvalumab plus irinotecan and cisplatin demonstrated potential among patients with extensive-stage small cell lung cancer.
According to results from the phase 2 REBORN trial, first-line durvalumab plus irinotecan and cisplatin demonstrated potential among patients with extensive-stage small cell lung cancer.
Results from the phase 3 IMforte trial demonstrated that lurbinectedin plus atezolizumab improved survival among patients with extensive-stage small cell lung cancer in the first-line maintenance setting.
Results from the phase 3 IMforte trial demonstrated that lurbinectedin plus atezolizumab improved survival among patients with extensive-stage small cell lung cancer in the first-line maintenance setting.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
